



News

Contact: Phil Oliva
IMS Health
(203)845-5345
poliva@imshealth.com

Tracy Everly
SDI
267-685-4387
teverly@sdihealth.com

Media Statement

IMS Health and SDI issued the following statement regarding their motion filed today with the First Circuit Court of Appeals. The companies requested a rehearing of the First Circuit's decision to overturn a New Hampshire U.S. District Court ruling that struck down the State's law banning the commercial use of prescriber-identifiable data.

"We have reviewed the First Circuit's decision and believe that there is a strong basis for a rehearing. We strongly believe the First Amendment protects the full dissemination of prescriber-identifiable data, which is vital to efforts to improve the quality, efficiency and safety of our healthcare system. Further, we agree with prior decisions that without these data the potential exists to compromise patient care."

About IMS

Operating in more than 100 countries, IMS Health is the world's leading provider of market intelligence to the pharmaceutical and healthcare industries. With \$2.2 billion in 2007 revenue and more than 50 years of industry experience, IMS offers leading-edge market intelligence products

and services that are integral to clients' day-to-day operations, including portfolio optimization capabilities; launch and brand management solutions; sales force effectiveness innovations; managed care and consumer health offerings; and consulting and services solutions that improve ROI and the delivery of quality healthcare worldwide. Additional information is available at <http://www.imshealth.com>.

About SDI

On July 29th, 2008 Verispan, LLC was acquired by SDI. Since 1982, SDI has been delivering innovative healthcare data products and analytic services to the pharmaceutical, biotech, healthcare, medical device, financial services, and consumer packaged goods industries. SDI is the leading provider of de-identified patient-level data analytics and offers a broad array of solutions and insights across the continuum of care. These include custom and syndicated patient-level data studies; localized disease and treatment surveillance and projection; market research audits; healthcare profiles; comprehensive managed care offerings; clinical trial optimization; direct-to-patient pharmacy programs; marketing effectiveness; sales targeting and compensation products; data integration, warehousing, and mining; list services; and direct marketing services. Its current roster includes the top 50 pharmaceutical/biotech companies. For more information, visit www.sdihealth.com or call 610.834.0800.